
## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5606634/publications.pdf Version: 2024-02-01

version. 2024-02-01



#	Article	IF	CITATIONS
1	Intrahepatic cholangiocyte regeneration from an Fgfâ€dependent extrahepatic progenitor niche in a zebrafishÂmodel of Alagille Syndrome. Hepatology, 2022, 75, 567-583.	7.3	12
2	Enhanced computed tomography features predict pancreatic neuroendocrine neoplasm with Ki-67 index less than 5%. European Journal of Radiology, 2022, 147, 110100.	2.6	1
3	Clinically relevant orthotopic xenograft models of patient-derived glioblastoma in zebrafish. DMM Disease Models and Mechanisms, 2022, 15, .	2.4	8
4	Development and Validation of a Novel Radiomics-Based Nomogram With Machine Learning to Preoperatively Predict Histologic Grade in Pancreatic Neuroendocrine Tumors. Frontiers in Oncology, 2022, 12, 843376.	2.8	2
5	Toripalimab combined with nab-paclitaxel/gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma: Updated results of a phase Ib/II clinical study Journal of Clinical Oncology, 2022, 40, e16244-e16244.	1.6	0
6	A phase I study of gemcitabine/nab-paclitaxel/S-1 chemotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma Journal of Clinical Oncology, 2022, 40, e16261-e16261.	1.6	0
7	Comparative efficacy and safety of neoadjuvant radiotherapy for patients with borderline resectable, and locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis protocol. BMJ Open, 2022, 12, e050558.	1.9	1
8	Case Report: Trastuzumab Treatment in Adenosquamous Carcinoma of the Extrahepatic Biliary Tract With Her-2 Amplification. Frontiers in Oncology, 2021, 11, 538328.	2.8	6
9	The efficacy of aprepitant in salvage treatment of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy for patients with gastrointestinal cancer. International Journal of Clinical Oncology, 2021, 26, 1091-1098.	2.2	0
10	Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation. OncoTargets and Therapy, 2021, Volume 14, 2815-2819.	2.0	2
11	Bevacizumab Combined with Sâ€1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study. Oncologist, 2021, 26, e1320-e1326.	3.7	3
12	Optimum adjuvant trastuzumab duration for human epidermal growth factor receptor-2 positive breast cancer: a network meta-analysis of randomized trials. Translational Cancer Research, 2021, 10, 1628-1643.	1.0	0
13	Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study. BMC Cancer, 2021, 21, 545.	2.6	2
14	Toripalimab with nab-paclitaxel/gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma: Updated results of a single-arm, open-label, phase Ib/II clinical study Journal of Clinical Oncology, 2021, 39, e16213-e16213.	1.6	3
15	The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma. Journal of Translational Medicine, 2021, 19, 301.	4.4	12
16	Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis. Pharmacological Research, 2021, 172, 105808.	7.1	20
17	Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein–Barr Virus-Associated Gastric Cancer. Frontiers in Oncology, 2021, 11, 759652.	2.8	3
18	Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma. BMC Cancer, 2020, 20, 636.	2.6	8

#	Article	IF	CITATIONS
19	Chemoradiotherapy Is Inferior to Chemotherapy Alone in Adjuvant Setting for Signet Ring Cell Containing Gastric Cancer. Frontiers in Oncology, 2020, 10, 570268.	2.8	3
20	Efficacy of chemotherapy combined with toripalimab in PD-L1–positive and high tumor mutation burden pancreatic acinar cell carcinoma: case report. Tumori, 2020, 107, 030089162098079.	1.1	4
21	The association between SNPs and hepatitis B virus related acute-on-chronic liver failure. Infection, Genetics and Evolution, 2020, 86, 104615.	2.3	0
22	Identification of gastrointestinal stromal tumors from leiomyomas in the esophagogastric junction. Medicine (United States), 2020, 99, e19884.	1.0	4
23	Alteration of Transforming Growth Factor Î <sup>2</sup> Signaling Pathway Predicts Worse Prognosis in Pancreatic Ductal Adenocarcinoma. Pancreas, 2020, 49, 534-542.	1.1	2
24	Apatinib treatment for unresectable gastrointestinal stromal tumor with synchronous gastric cancer. Precision Clinical Medicine, 2020, 3, 67-70.	3.3	4
25	Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma. Frontiers in Immunology, 2020, 11, 1127.	4.8	9
26	Optimal dose-fractionation schedule of palliative radiotherapy for patients with bone metastases: a protocol for systematic review and network meta-analysis. BMJ Open, 2020, 10, e033120.	1.9	3
27	Oncogene-dependent function of BRG1 in hepatocarcinogenesis. Cell Death and Disease, 2020, 11, 91.	6.3	23
28	An Unexpected Case Report of Adrenal Lymphangioma: Mimicking Metastatic Tumor on Imaging in a Patient With Pancreatic Cancer. Frontiers in Endocrinology, 2020, 11, 610744.	3.5	1
29	Combined recombinant humanized anti-PD-1 monoclonal antibody (JS001) and nab-paclitaxel/gemcitabine (AG) as the first-line therapy for patients with advanced pancreatic adenocarcinoma: Preliminary results of an open-label, phase Ib/II clinical study Journal of Clinical Oncology, 2020, 38, e16792-e16792.	1.6	0
30	Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials. BMJ Open, 2020, 10, e035802.	1.9	1
31	Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials. BMJ Open, 2020, 10, e035802.	1.9	1
32	PEG-derivatized birinapant as a nanomicellar carrier of paclitaxel delivery for cancer therapy. Colloids and Surfaces B: Biointerfaces, 2019, 182, 110356.	5.0	5
33	Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma. Radiation Oncology, 2019, 14, 120.	2.7	16
34	Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor. Frontiers in Oncology, 2019, 9, 470.	2.8	7
35	S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial. Oncologist, 2019, 24, 591-e165.	3.7	11
36	Reconstruction and Analysis of the Differentially Expressed IncRNA-miRNA-mRNA Network Based on Competitive Endogenous RNA in Hepatocellular Carcinoma. Critical Reviews in Eukaryotic Gene Expression, 2019, 29, 539-549.	0.9	10

#	Article	IF	CITATIONS
37	<ppplication chemotherapy="" combined="" glucagonoma<br="" heterogeneous="" in="" of="" somatostatin,="" tae="" with="">Presented with Necrolytic Migratory Erythema. OncoTargets and Therapy, 2019, Volume 12, 11339-11344.</ppplication>	2.0	1
38	Alteration of TGF-β signaling pathway predicts worse prognosis in pancreatic ductal adenocarcinoma Journal of Clinical Oncology, 2019, 37, e13006-e13006.	1.6	0
39	Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced hepatocellular carcinoma Journal of Clinical Oncology, 2019, 37, e15606-e15606.	1.6	0
40	ETV2 mediates endothelial transdifferentiation of glioblastoma. Signal Transduction and Targeted Therapy, 2018, 3, 4.	17.1	33
41	RhoAâ€stimulated intraâ€capillary morphology switch facilitates the arrest of individual circulating tumor cells. International Journal of Cancer, 2018, 142, 2094-2105.	5.1	13
42	Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib. Medicine (United States), 2018, 97, e13113.	1.0	17
43	CXCR2 is a novel cancer stem-like cell marker for triple-negative breast cancer. OncoTargets and Therapy, 2018, Volume 11, 5559-5567.	2.0	14
44	Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1339-1346.	2.5	8
45	Tumoral cavitation in colorectal cancer patients with lung metastasis treated with bevacizumab and chemotherapy Journal of Clinical Oncology, 2018, 36, e15565-e15565.	1.6	0
46	Both <i>de novo</i> synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells. Liver International, 2017, 37, 80-89.	3.9	60
47	Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. Journal of Hepatology, 2017, 67, 1194-1203.	3.7	77
48	Identify a Blood-Brain Barrier Penetrating Drug-TNB using Zebrafish Orthotopic Glioblastoma Xenograft Model. Scientific Reports, 2017, 7, 14372.	3.3	35
49	5-Azacytidine promotes invadopodia formation and tumor metastasis through the upregulation of PI3K in ovarian cancer cells. Oncotarget, 2017, 8, 60173-60187.	1.8	6
50	The accumulation of macrophages attenuates the effect of recombinant human endostatin on lung cancer. OncoTargets and Therapy, 2016, Volume 9, 6581-6595.	2.0	4
51	A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with RO gastrectomy and D2 lymph node dissection. Gastric Cancer, 2016, 19, 245-254.	5.3	7
52	Silencing stem cell factor attenuates stemness and inhibits migration of cancer stem cells derived from Lewis lung carcinoma cells. Tumor Biology, 2016, 37, 7213-7227.	1.8	12
53	Endostatin improves cancer-associated systemic syndrome in a lung cancer model. Oncology Letters, 2015, 9, 2023-2030.	1.8	1
54	Bleeding after Bevacizumab Treatment in Patients with Metastatic Colorectal Cancer. Tumori, 2015, 101, 46-51.	1.1	8

#	Article	IF	CITATIONS
55	A phase I study of adjuvant intensity-modulated radiotherapy with concurrent paclitaxel and cisplatin for cervical cancer patients with high risk factors. Medical Oncology, 2015, 32, 247.	2.5	4
56	Versican silencing improves the antitumor efficacy of endostatin by alleviating its induced inflammatory and immunosuppressive changes in the tumor microenvironment. Oncology Reports, 2015, 33, 2981-2991.	2.6	32
57	Matched-pair comparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer: A systematic review and meta-analysis. Radiotherapy and Oncology, 2014, 112, 250-255.	0.6	82
58	Loss of RASSF1A Expression in Colorectal Cancer and Its Association with K-ras Status. BioMed Research International, 2013, 2013, 1-7.	1.9	16
59	Successful treatment of liver metastasis from solid pseudopapillary tumor of the pancreas: a. Wspolczesna Onkologia, 2013, 4, 400-403.	1.4	3
60	Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC Cancer, 2009, 9, 432.	2.6	173